Katsiaryna Bykov, Sc.D., Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Interactions | 11 | 2021 | 1465 | 2.780 |
Why?
|
| Cross-Over Studies | 4 | 2020 | 1950 | 1.770 |
Why?
|
| Serotonin Uptake Inhibitors | 5 | 2022 | 1425 | 1.450 |
Why?
|
| Analgesics, Opioid | 6 | 2022 | 3037 | 1.050 |
Why?
|
| Ticlopidine | 3 | 2017 | 910 | 0.890 |
Why?
|
| Rhabdomyolysis | 2 | 2019 | 152 | 0.880 |
Why?
|
| Oxycodone | 1 | 2022 | 119 | 0.840 |
Why?
|
| Drug Evaluation | 2 | 2020 | 688 | 0.800 |
Why?
|
| Warfarin | 4 | 2022 | 1433 | 0.760 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 32 | 0.750 |
Why?
|
| Metoprolol | 1 | 2018 | 95 | 0.720 |
Why?
|
| Hemophilia B | 1 | 2017 | 69 | 0.690 |
Why?
|
| Factor VIIa | 1 | 2017 | 93 | 0.680 |
Why?
|
| Pharmacoepidemiology | 1 | 2020 | 292 | 0.670 |
Why?
|
| Pyridones | 1 | 2022 | 639 | 0.670 |
Why?
|
| Pain, Postoperative | 5 | 2021 | 1516 | 0.670 |
Why?
|
| Antithrombins | 2 | 2019 | 295 | 0.660 |
Why?
|
| Drug Utilization | 3 | 2020 | 1248 | 0.630 |
Why?
|
| Cardiovascular Agents | 4 | 2015 | 889 | 0.630 |
Why?
|
| Epidemiologic Research Design | 1 | 2019 | 373 | 0.610 |
Why?
|
| Data Mining | 1 | 2021 | 548 | 0.600 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 354 | 0.590 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 3016 | 0.580 |
Why?
|
| Hemophilia A | 1 | 2017 | 296 | 0.570 |
Why?
|
| Medication Adherence | 5 | 2018 | 1990 | 0.510 |
Why?
|
| Myocardial Infarction | 6 | 2018 | 11266 | 0.510 |
Why?
|
| Research Design | 4 | 2021 | 5835 | 0.500 |
Why?
|
| Electronic Health Records | 2 | 2019 | 3836 | 0.480 |
Why?
|
| Anticoagulants | 4 | 2022 | 4173 | 0.470 |
Why?
|
| Hemorrhage | 3 | 2019 | 3149 | 0.460 |
Why?
|
| Pyrazoles | 1 | 2022 | 1907 | 0.440 |
Why?
|
| Thromboembolism | 1 | 2017 | 988 | 0.440 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 1429 | 0.410 |
Why?
|
| Inpatients | 1 | 2021 | 2050 | 0.410 |
Why?
|
| Clarithromycin | 2 | 2020 | 75 | 0.400 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 1038 | 0.390 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 2592 | 0.380 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 112 | 0.370 |
Why?
|
| Insurance, Health | 2 | 2020 | 2479 | 0.350 |
Why?
|
| Databases, Factual | 11 | 2021 | 7865 | 0.350 |
Why?
|
| Cohort Studies | 14 | 2022 | 38732 | 0.340 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 1659 | 0.340 |
Why?
|
| Cholesterol | 1 | 2016 | 2751 | 0.330 |
Why?
|
| Treatment Failure | 1 | 2012 | 2697 | 0.310 |
Why?
|
| Case-Control Studies | 4 | 2021 | 21684 | 0.310 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2016 | 2963 | 0.310 |
Why?
|
| Data Collection | 1 | 2015 | 3321 | 0.300 |
Why?
|
| Cerebral Hemorrhage | 2 | 2016 | 2436 | 0.300 |
Why?
|
| Healthcare Disparities | 3 | 2016 | 2972 | 0.300 |
Why?
|
| Propensity Score | 8 | 2020 | 1751 | 0.290 |
Why?
|
| Patient Readmission | 1 | 2018 | 2917 | 0.270 |
Why?
|
| Parkinson Disease | 2 | 2016 | 2465 | 0.270 |
Why?
|
| Medicare | 1 | 2020 | 5077 | 0.260 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 4958 | 0.240 |
Why?
|
| Humans | 43 | 2022 | 686663 | 0.230 |
Why?
|
| Middle Aged | 23 | 2022 | 216468 | 0.230 |
Why?
|
| United States | 13 | 2021 | 65579 | 0.230 |
Why?
|
| Drug Substitution | 2 | 2016 | 300 | 0.230 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 4466 | 0.230 |
Why?
|
| Paroxetine | 1 | 2022 | 174 | 0.220 |
Why?
|
| Methods | 1 | 2021 | 1253 | 0.220 |
Why?
|
| Baclofen | 1 | 2021 | 120 | 0.220 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2015 | 472 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2015 | 1561 | 0.210 |
Why?
|
| Stroke | 3 | 2017 | 8730 | 0.210 |
Why?
|
| Lorazepam | 1 | 2021 | 144 | 0.210 |
Why?
|
| Control Groups | 1 | 2019 | 89 | 0.200 |
Why?
|
| Aged | 20 | 2022 | 162271 | 0.200 |
Why?
|
| Drugs, Generic | 2 | 2016 | 474 | 0.200 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 6632 | 0.190 |
Why?
|
| Coronary Artery Bypass | 3 | 2015 | 2509 | 0.190 |
Why?
|
| Male | 25 | 2022 | 352465 | 0.190 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 296 | 0.180 |
Why?
|
| Insurance Claim Review | 2 | 2021 | 768 | 0.180 |
Why?
|
| Azithromycin | 1 | 2019 | 178 | 0.180 |
Why?
|
| Simvastatin | 1 | 2020 | 350 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2021 | 1861 | 0.170 |
Why?
|
| Fluoxetine | 1 | 2022 | 766 | 0.170 |
Why?
|
| Female | 26 | 2022 | 375459 | 0.170 |
Why?
|
| Prescription Drugs | 2 | 2015 | 607 | 0.170 |
Why?
|
| Computer Simulation | 3 | 2020 | 6120 | 0.160 |
Why?
|
| Hospitalization | 5 | 2022 | 9304 | 0.160 |
Why?
|
| Names | 1 | 2015 | 55 | 0.150 |
Why?
|
| Aortic Aneurysm | 1 | 2020 | 712 | 0.150 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2015 | 132 | 0.150 |
Why?
|
| Ketorolac | 1 | 2015 | 66 | 0.140 |
Why?
|
| Community Pharmacy Services | 1 | 2014 | 44 | 0.140 |
Why?
|
| Aneurysm, Dissecting | 1 | 2020 | 692 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 2256 | 0.140 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 986 | 0.140 |
Why?
|
| Adult | 15 | 2022 | 211400 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2022 | 67320 | 0.130 |
Why?
|
| Time Factors | 4 | 2022 | 42271 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2022 | 3975 | 0.130 |
Why?
|
| Information Systems | 1 | 2015 | 386 | 0.130 |
Why?
|
| Risk Factors | 9 | 2021 | 69278 | 0.130 |
Why?
|
| Prevalence | 2 | 2021 | 14744 | 0.130 |
Why?
|
| Osteoarthritis, Hip | 1 | 2017 | 381 | 0.120 |
Why?
|
| Anti-Ulcer Agents | 1 | 2013 | 117 | 0.120 |
Why?
|
| Thrombophilia | 1 | 2015 | 322 | 0.120 |
Why?
|
| Models, Theoretical | 2 | 2015 | 3621 | 0.120 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 171 | 0.120 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 495 | 0.120 |
Why?
|
| Cephalosporins | 1 | 2013 | 215 | 0.120 |
Why?
|
| Recurrence | 2 | 2022 | 8198 | 0.120 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 903 | 0.120 |
Why?
|
| Algorithms | 1 | 2012 | 13500 | 0.110 |
Why?
|
| Tamoxifen | 1 | 2016 | 975 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 785 | 0.110 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12525 | 0.110 |
Why?
|
| Financing, Personal | 1 | 2014 | 319 | 0.110 |
Why?
|
| Logistic Models | 4 | 2020 | 13807 | 0.110 |
Why?
|
| Reminder Systems | 1 | 2014 | 391 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 1713 | 0.110 |
Why?
|
| Comorbidity | 3 | 2022 | 10648 | 0.110 |
Why?
|
| Neoplasms | 1 | 2019 | 19538 | 0.110 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 273 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2019 | 60991 | 0.100 |
Why?
|
| Vancomycin | 1 | 2013 | 502 | 0.100 |
Why?
|
| African Americans | 2 | 2015 | 5144 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 442 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 6829 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2015 | 1848 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2015 | 759 | 0.090 |
Why?
|
| Hospitals | 1 | 2021 | 2930 | 0.090 |
Why?
|
| Young Adult | 7 | 2020 | 56052 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 3797 | 0.090 |
Why?
|
| Pneumonia | 2 | 2020 | 1942 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 683 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 604 | 0.090 |
Why?
|
| Cesarean Section | 1 | 2016 | 1233 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 1542 | 0.080 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 1101 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 7060 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2020 | 10108 | 0.080 |
Why?
|
| Pain | 1 | 2022 | 4295 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 1336 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2018 | 2754 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 1325 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 59331 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 1683 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2015 | 1941 | 0.070 |
Why?
|
| Incidence | 3 | 2020 | 20496 | 0.070 |
Why?
|
| Risk | 1 | 2017 | 9915 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1714 | 0.070 |
Why?
|
| Self Report | 1 | 2015 | 3341 | 0.070 |
Why?
|
| Seizures | 1 | 2016 | 2410 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 2062 | 0.070 |
Why?
|
| Cross Infection | 1 | 2013 | 1387 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2019 | 5104 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1464 | 0.060 |
Why?
|
| Benzodiazepines | 2 | 2021 | 1040 | 0.060 |
Why?
|
| Depression | 1 | 2022 | 6805 | 0.060 |
Why?
|
| Epilepsy | 1 | 2016 | 2828 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 5182 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7933 | 0.050 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 95 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2017 | 23953 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2017 | 41159 | 0.050 |
Why?
|
| Smoking | 2 | 2016 | 9029 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 13413 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 4038 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2021 | 470 | 0.050 |
Why?
|
| Infant | 2 | 2017 | 33918 | 0.050 |
Why?
|
| Adolescent | 5 | 2017 | 84957 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39737 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2016 | 6378 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 4928 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2016 | 160 | 0.040 |
Why?
|
| Etodolac | 1 | 2015 | 21 | 0.040 |
Why?
|
| Risk Assessment | 5 | 2015 | 23739 | 0.040 |
Why?
|
| Child | 3 | 2017 | 71361 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 759 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2015 | 245 | 0.030 |
Why?
|
| New Jersey | 1 | 2013 | 271 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2015 | 1795 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 452 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 1095 | 0.030 |
Why?
|
| Embolism | 1 | 2015 | 386 | 0.030 |
Why?
|
| Peptic Ulcer | 1 | 2013 | 213 | 0.030 |
Why?
|
| Lactones | 1 | 2015 | 349 | 0.030 |
Why?
|
| Health Services Misuse | 1 | 2014 | 245 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2013 | 651 | 0.030 |
Why?
|
| Back Pain | 1 | 2016 | 527 | 0.030 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2014 | 344 | 0.030 |
Why?
|
| Telephone | 1 | 2014 | 615 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 470 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15083 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 2963 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12734 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 19153 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1250 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2015 | 1564 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 1444 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 3057 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 941 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2016 | 1875 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2016 | 6669 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1505 | 0.020 |
Why?
|
| Migraine Disorders | 1 | 2016 | 1486 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 2764 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 6241 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 7110 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2015 | 49071 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3150 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 11616 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 4253 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 9337 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 25703 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 10088 | 0.010 |
Why?
|